Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05492734 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Feasibility of Non-invasive Dried Blood Sampling
A Phase 1 study, sponsored by Edgewise Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT05492734 is a Phase 1 study that has completed, run by Edgewise Therapeutics. The registered enrollment target is 10 participants.
The verdict
NCT05492734, a Phase 1 study, has completed, sponsored by Edgewise Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
This is a Phase I, open-label, single-dose, 1-period study to compare EDG-5506 concentrations measured from venous and capillary blood sampling in healthy adult subjects. EDG-5506 is an investigational product designed to selectively modulate a fast skeletal muscle motor protein called myosin that is part of the contraction machinery of the damage-prone muscle fibers.
Interventions
- DRUG EDG-5506
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2022-08-12 |
| Est. Completion | 2022-08-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05492734
The ClinicalTrials.gov registry entry for NCT05492734 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Edgewise Therapeutics, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which EDG-5506 is the first listed.
NCT05492734 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05492734 about?
NCT05492734 is a clinical study titled "A Study to Assess the Feasibility of Non-invasive Dried Blood Sampling". This is a Phase I, open-label, single-dose, 1-period study to compare EDG-5506 concentrations measured from venous and capillary blood sampling in healthy adult subjects. EDG-5506 is an investigational product designed to selectively modulate a fast skeletal muscle motor protein called myosin that ...
What is the current status of trial NCT05492734?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2022-08-12. Estimated completion is 2022-08-19.
What interventions are being tested in trial NCT05492734?
The interventions under investigation include: EDG-5506 (DRUG).
Who is sponsoring clinical trial NCT05492734?
This trial is sponsored by Edgewise Therapeutics, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.